Evidence map›Paper›PMID 40012376›Full record

ArticleCurrent pharmaceutical design2025

Mei-Feng Shi, Xiao-Na Ma, Fang-Shu Zou, Wei Feng, Qiang Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pharmaceutics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mei-Feng ShiState Key Laboratory of Traditional Chinese Medicine Syndrome, The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Xiao-Na MaState Key Laboratory of Traditional Chinese Medicine Syndrome, The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Fang-Shu ZouState Key Laboratory of Traditional Chinese Medicine Syndrome, The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Wei FengState Key Laboratory of Traditional Chinese Medicine Syndrome, The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Qiang XuState Key Laboratory of Traditional Chinese Medicine Syndrome, The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.

Funding

Natural Science Foundation of the Department of Education of Guangdong Province 2022KTSCX030
6 · The paper itself

Abstract

purposeLiquidambaris Fructus (LF), a prevalent Chinese medicinal herb, has been effectively utilized in the clinical treatment of rheumatoid arthritis (RA). Coniferin, is the active ingredient in LF, and there is a paucity of research examining its potential anti-RA properties. This study employs

methods

resultsIt was observed that coniferin promotes apoptosis of RA-FLSs through the PTGS2/Apoptosis signaling pathway and inhibits the proliferation, migration, and invasion of RA-FLSs, with anti-inflammatory, oxidative stress-reducing, and mitochondrial transmembrane potential disruption effects.

conclusionThe potential mechanism of coniferin for the treatment of RA is to promote apoptosis of RAFLSs by intervening in the PTGS2/apoptosis signaling pathway.

Indexed as

ApoptosisArthritis, RheumatoidComputer SimulationCyclooxygenase 2Cell MovementCell ProliferationCells, CulturedHumansMolecular Docking SimulationSynoviocytesCyclooxygenase 2PTGS2 protein, humanapoptosisconiferinfibroblast-like synoviocytes.Liquidambaris fructusPTGS2/apoptosis signaling pathwayrheumatoid arthritis

Identifiers

PMID40012376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.